Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Current Leases (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of Current Leases data on record, last reported at $379000.0 in Q3 2025.

  • For Q3 2025, Current Leases rose 7.06% year-over-year to $379000.0; the TTM value through Sep 2025 reached $379000.0, up 7.06%, while the annual FY2024 figure was $185000.0, 86.54% down from the prior year.
  • Current Leases reached $379000.0 in Q3 2025 per CRVS's latest filing, up from $355000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $1.4 million in Q4 2023 and bottomed at $185000.0 in Q4 2024.
  • Average Current Leases over 4 years is $882533.3, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Current Leases: increased 15.87% in 2023, then crashed 86.54% in 2024.
  • A 4-year view of Current Leases shows it stood at $1.2 million in 2022, then grew by 11.89% to $1.4 million in 2023, then plummeted by 86.54% to $185000.0 in 2024, then skyrocketed by 104.86% to $379000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $379000.0 in Q3 2025, $355000.0 in Q2 2025, and $319000.0 in Q1 2025.